{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:58Z","timestamp":1792112278875,"version":"4.4.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NeuroRX"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.nurx.2006.01.009","type":"journal-article","created":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T12:40:16Z","timestamp":1143204016000},"page":"192-206","source":"Crossref","is-referenced-by-count":258,"title":["Contemporary assessment and pharmacotherapy of Tourette syndrome"],"prefix":"10.1007","volume":"3","author":[{"given":"Lawrence","family":"Scahill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Erenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheston M.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kurlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samual","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Walkup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"30200192_CR1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMra010032","volume":"345","author":"J Jankovic","year":"2001","unstructured":"Jankovic J. Tourette\u2019s syndrome.N Engl J Med 345: 1184\u20131192, 2001.","journal-title":"N Engl J Med"},{"key":"30200192_CR2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)11526-1","volume":"360","author":"JF Leckman","year":"2002","unstructured":"Leckman JF. Tourette\u2019s syndrome.Lancet 360: 1577\u20131586, 2002.","journal-title":"Lancet"},{"key":"30200192_CR3","first-page":"319","volume":"85","author":"J Piacentini","year":"2001","unstructured":"Piacentini J, Chang S. Behavioral treatments for Tourette syndrome and tic disorders: state of the art.Adv Neurol 85: 319\u2013331, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0025-7125(05)70332-1","volume":"85","author":"WE Craighead","year":"2001","unstructured":"Craighead WE, Craighead LW. The role of psychotherapy in treating psychiatric disorders.Med Clin North Am 85: 617\u2013629, 2001.","journal-title":"Med Clin North Am"},{"key":"30200192_CR5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0006-3223(02)01552-4","volume":"52","author":"EB Foa","year":"2002","unstructured":"Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?Biol Psychiatry 52: 987\u2013997, 2002.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1005174913412","volume":"28","author":"KC Wells","year":"2000","unstructured":"Wells KC, Pelham WE, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation.J Abnorm Child Psychol 28: 483\u2013505, 2000.","journal-title":"J Abnorm Child Psychol"},{"key":"30200192_CR7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/appi.ajp.160.6.1175","volume":"160","author":"S Wilhelm","year":"2003","unstructured":"Wilhelm S, Deckersbach T, Coffey BJ, Bohne A, Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourette\u2019s disorder: a randomized controlled trial.Am J Psychiatry 160: 1175\u20131177, 2003.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mds.10649","volume":"19","author":"Y Temel","year":"2004","unstructured":"Temel Y, Visser-Vandewalle V. Surgery in Tourette syndrome.Mov Disord 19: 3\u201314, 2004.","journal-title":"Mov Disord"},{"key":"30200192_CR9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/jnnp.2004.043273","volume":"76","author":"JL Houeto","year":"2005","unstructured":"Houeto JL, Karachi C, Mallet L, Pillon B, Yelnik J, Mesnage V et al. Tourette\u2019s syndrome and deep brain stimulation.J Neurol Neurosurg Psychiatry 76: 992\u2013995, 2005.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"30200192_CR10","first-page":"31","volume":"85","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Kompoliti K. Rating scales and quantitative assessment of tics.Adv Neurol 85: 31\u201342, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR11","first-page":"310","volume-title":"Tourette\u2019s syndrome: tics, obsessions, compulsions: developmental psychopathology and clinical care","author":"L Scahill","year":"1999","unstructured":"Scahill L, King RA, Schultz RT, Leckman JF. Selection and use of diagnostic and clinician rating instruments. In: Tourette\u2019s syndrome: tics, obsessions, compulsions: developmental psychopathology and clinical care (Leckman JF, Cohen DJ, eds), pp 310\u2013324. New York: Wiley, 1999."},{"key":"30200192_CR12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF Leckman","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity.J Am Acad Child Adolesc Psychiatry 28: 566\u2013573, 1989.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","volume":"36","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle M, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK et al. Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity.J Am Acad Child Adolesc Psychiatry 36: 844\u2013852, 1997.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR14","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/mds.10618","volume":"18","author":"C Kwak","year":"2003","unstructured":"Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette\u2019s syndrome.Mov Disord 18: 1530\u20131533. 2003.","journal-title":"Mov Disord"},{"key":"30200192_CR15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/archneur.1993.00540100012008","volume":"50","author":"The Tourette Syndrome Classification Group","year":"1993","unstructured":"The Tourette Syndrome Classification Group. Definitions and classifications of tic disorders.Arch Neurol 50: 1013\u20131016, 1993.","journal-title":"Arch Neurol"},{"key":"30200192_CR16","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual, fourth edition: treatment revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual, fourth edition: treatment revision. Washington, DC: American Psychiatric Association Press, 2000."},{"key":"30200192_CR17","first-page":"15","volume":"85","author":"J Jankovic","year":"2001","unstructured":"Jankovic J. Differential diagnosis and etiology of tics.Adv Neurol 85: 15\u201329, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR18","first-page":"245","volume":"85","author":"A Rothenberger","year":"2001","unstructured":"Rothenberger A, Kostanecka T, Kinkelbur J, Cohrs S, Woerner W, Hajak G. Sleep and Tourette syndrome.Adv Neurol 85: 245\u2013259, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3999(02)00602-5","volume":"55","author":"T Kostanecka-Endress","year":"2003","unstructured":"Kostanecka-Endress T, Banaschewski T, Kinkelbur J, Wullner I, Lichtblau S, Cohrs S et al. Disturbed sleep in children with Tourette syndrome: a polysomnographic study.J Psychosom Res 55: 23\u201329, 2003.","journal-title":"J Psychosom Res"},{"key":"30200192_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archpsyc.58.5.427","volume":"58","author":"BS Peterson","year":"2001","unstructured":"Peterson, BS, Staib L, Scahill L, Zhang H, Anderson C, Leckman JF et al. Regional brain and ventricular volumes in Tourette syndrome.Arch Gen Psychiatry 58: 427\u2013440, 2001.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1176\/appi.ajp.159.8.1329","volume":"159","author":"HS Singer","year":"2002","unstructured":"Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR et al. Elevated intrasynaptic dopamine release in Tourette\u2019s syndrome measured by PET.Am J Psychiatry 159: 1329\u20131336. 2002.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.60.4.415","volume":"60","author":"BS Peterson","year":"2003","unstructured":"Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R et al. Basal ganglia volumes in patients with Gilles de la Tourette syndrome.Arch Gen Psychiatry 60: 415\u2013424, 2003.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0733-8619(05)70315-7","volume":"15","author":"R Kumar","year":"1997","unstructured":"Kumar R, Lang AE. Tourette syndrome: secondary tic disorders.Neurol Clin 15: 309\u2013331, 1997.","journal-title":"Neurol Clin"},{"key":"30200192_CR24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0006-3223(03)00704-2","volume":"55","author":"TK Murphy","year":"2004","unstructured":"Murphy TK, Sajid M, Soto O, Shapira N, Edge P, Yang M. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics.Biol Psychiatry 55: 61\u201368, 2004.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR25","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.mp.4001170","volume":"7","author":"SE Swedo","year":"2002","unstructured":"Swedo SE. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS).Mol Psychiatry 7: S24-S25, 2002.","journal-title":"Mol Psychiatry"},{"key":"30200192_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0733-8619(05)70316-9","volume":"15","author":"JJ Hallett","year":"1997","unstructured":"Hallett JJ, Kiessling LS. Neuroimmunology of tics and other childhood hyperkinesias.Neurol Clin 15: 333\u2013344, 1997.","journal-title":"Neurol Clin"},{"key":"30200192_CR27","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/WNL.50.6.1618","volume":"50","author":"HS Singer","year":"1998","unstructured":"Singer HS, Guiliano JD, Hansen BH, Hallett JJ, Laurino JP, Benson M et al. Antiobodies against human putamen in children with Tourette syndrome.Neurology 50: 1618\u20131624, 1998.","journal-title":"Neurology"},{"key":"30200192_CR28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0006-3223(01)01096-4","volume":"50","author":"SA Morshed","year":"2001","unstructured":"Morshed SA, Parveen S, Leckman JF, Mercadante MT, Bittencourt Kiss MH, Miguel EC et al. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette\u2019s syndrome, Sydenham\u2019s chorea, and autoimmune disorders.Biol Psychiatry 50: 566\u2013577, 2001.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0887-8994(02)00507-6","volume":"28","author":"CR Loiselle","year":"2003","unstructured":"Loiselle CR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal, and nuclear antibodies in Tourette syndrome.Pediatr Neurol 28: 119\u2013125, 2003.","journal-title":"Pediatr Neurol"},{"key":"30200192_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0165-5728(00)00320-9","volume":"111","author":"JJ Hallett","year":"2000","unstructured":"Hallett JJ, Harling-Berg CJ, Knopf PM, Stopa EG, Kiessling LS. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction.J Neuroimmunol 111: 195\u2013202, 2000.","journal-title":"J Neuroimmunol"},{"key":"30200192_CR31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1176\/appi.ajp.159.4.657","volume":"159","author":"JR Taylor","year":"2002","unstructured":"Taylor JR, Morshed SA, Parveen S, Mercadante MT, Scahill L, Peterson BS et al. An animal model of Tourette\u2019s syndrome.Am J Psychiatry 159: 657\u2013660, 2002.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jnnp.74.5.602","volume":"74","author":"AJ Church","year":"2003","unstructured":"Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM. Tourette\u2019s syndrome: a cross sectional study to examine the PANDAS hypothesis.J Neurol Neurosurg Psychiatry 74: 602\u2013607. 2003.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"30200192_CR33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mds.10522","volume":"19","author":"CR Loiselle","year":"2004","unstructured":"Loiselle CR, Lee O, Moran TH, Singer HS. Striatal microinfusion of Tourette syndrome and PANDAS sera: failure to induce behavioral changes.Mov Disord 19: 390\u2013396, 2004.","journal-title":"Mov Disord"},{"key":"30200192_CR34","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0006-3223(99)00020-7","volume":"45","author":"MA Garvey","year":"1999","unstructured":"Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, Lougee L, Leonard HL et al. A pilot study of penicillin prophylaxis for neuropsychiatrie exacerbations triggered by streptococcal infections.Biol Psychiatry 45: 1564\u20131571, 1999.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"SJ Perlmutter","year":"1999","unstructured":"Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.Lancet 354: 1153\u20131158, 1999.","journal-title":"Lancet"},{"key":"30200192_CR36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.Arch Gen Psychiatry 46: 1006\u20131011, 1989.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Rice LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity.Arch Gen Psychiatry 46: 1012\u20131016, 1989.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S0033291700040010","volume":"1","author":"J Cooper","year":"1970","unstructured":"Cooper J. The Leyton obsessional inventory.Psychol Med 1: 48\u201364, 1970.","journal-title":"Psychol Med"},{"key":"30200192_CR39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0002-7138(09)60602-6","volume":"25","author":"CJ Berg","year":"1986","unstructured":"Berg CJ, Rapoport JL, Flament M. The Leyton obsessional inventory: child version.J Am Acad Child Adolesc Psychiatry 25: 84\u201391, 1986.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00004583-198811000-00017","volume":"27","author":"CZ Berg","year":"1988","unstructured":"Berg CZ, Whitaker A, Davies M, Flament MF, Rapoport JL. The survey form of the Leyton obsessional inventory: child version. Norms from an epidemiological study.J Am Acad Child Adolesc Psychiatry 27: 759\u2013763, 1988.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/ajp.151.5.675","volume":"151","author":"JF Leckman","year":"1994","unstructured":"Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. \u201cJust right\u201d perceptions associated with compulsive behavior in Tourette\u2019s syndrome.Am J Psychiatry 151: 675\u2013680, 1994.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00919127","volume":"6","author":"CH Goyette","year":"1978","unstructured":"Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating scales.J Abnorm Child Psychol 6: 221\u2013236, 1978.","journal-title":"J Abnorm Child Psychol"},{"key":"30200192_CR43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/073428299801600104","volume":"16","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, McGoey KE, Ikeda MJ, Anastopoulos AD. Reliability and validity of parent and teacher ratings of attention-deficit\/hyperactivity disorder symptoms.J Psychoeduc Assess 16: 55\u201368, 1998.","journal-title":"J Psychoeduc Assess"},{"key":"30200192_CR44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0031-3955(05)70168-1","volume":"46","author":"J Swanson","year":"1999","unstructured":"Swanson J, Lerner M, March J, Gresham FM. Assessment and intervention for attention-deficit\/hyperactivity disorder in the schools: lessons from the MTA study.Pediatr Clin North Am 46: 993\u20131009, 1999.","journal-title":"Pediatr Clin North Am"},{"key":"30200192_CR45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","volume":"56","author":"MTA Cooperative Group","year":"1999","unstructured":"MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD: a 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder.Arch Gen Psychiatry 56: 1073, 1999.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/0894-4105.12.1.134","volume":"12","author":"RT Schultz","year":"1998","unstructured":"Schultz RT, Carter AS, Gladstone M, Scahill L, Leckman JF, Peterson BS et al. Visual-motor integration functioning in children with Tourette syndrome.Neuropsychology 12: 134\u2013145, 1998.","journal-title":"Neuropsychology"},{"key":"30200192_CR47","first-page":"103","volume":"85","author":"PG Como","year":"2001","unstructured":"Como PG. Neuropsychological function in Tourette syndrome.Adv Neurol 85: 103\u2013111, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR48","first-page":"457","volume":"31","author":"KO Jobson","year":"1995","unstructured":"Jobson KO, Potter WZ. International Psychopharmacology Algorithim Project Report: introduction.Psychopharmacol Bull 31: 457\u2013459, 1995.","journal-title":"Psychopharmacol Bull"},{"key":"30200192_CR49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1176\/ajp.135.5.585","volume":"135","author":"MS Ross","year":"1978","unstructured":"Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette syndrome.Am J Psychiatry 135: 585\u2013587, 1978.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004583-198403000-00007","volume":"23","author":"AK Shapiro","year":"1984","unstructured":"Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette\u2019s syndrome.J Am Acad Child Adolesc Psychiatry 23: 161\u2013173, 1984.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette\u2019s syndrome.Arch Gen Psychiatry 46: 722\u2013730, 1989.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR52","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"FR Sallee","year":"1997","unstructured":"Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder.Am J Psychiatry 154: 1057\u20131062, 1997.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0733-8619(05)70321-2","volume":"15","author":"R Kurlan","year":"1997","unstructured":"Kurlan R. Treatment of tics.Neurol Clin North Am 15: 403\u2013409, 1997.","journal-title":"Neurol Clin North Am"},{"key":"30200192_CR54","first-page":"343","volume":"85","author":"MA Riddle","year":"2001","unstructured":"Riddle MA, Carlson J. Clinical psychopharmacology for Tourette syndrome and associated disorders.Adv Neurol 85: 343\u2013354, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1056-4993(18)30137-8","volume":"9","author":"L Scahill","year":"2000","unstructured":"Scahill L, Chappell PB, King RA, Leckman JF. Pharmacological treatment of tic disorders.Child Adolesc Psychiatr Clin North Am 9: 99\u2013117, 2000.","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"30200192_CR56","first-page":"377","volume":"35","author":"RL Borison","year":"1982","unstructured":"Borison RL, Ang L, Chang S, Dysken M, Comaty JE, Davis JM. New pharmacological approaches in the treatment of Tourette syndrome.Adv Neurol 35: 377\u2013382, 1982.","journal-title":"Adv Neurol"},{"key":"30200192_CR57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","volume":"41","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders.Arch Neurol 41: 271\u2013272, 1984.","journal-title":"Arch Neurol"},{"key":"30200192_CR58","doi-asserted-by":"crossref","first-page":"A506","DOI":"10.1212\/01.WNL.0000106827.39764.7E","volume":"62","author":"YS Silay","year":"2004","unstructured":"Silay YS, Vuong KD, Jankovic J. The efficacy and safety of fluphenazine in patients with tourette syndrome.Neurology 62: A506, 2004.","journal-title":"Neurology"},{"key":"30200192_CR59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.136.3.317","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary disorders.Am J Psychiatry 136: 317\u2013320, 1979.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.J Clin Psychopharmacol 22: 31\u201339, 2002.","journal-title":"J Clin Psychopharmacol"},{"key":"30200192_CR61","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome.Neurology 60: 1130\u20131135, 2003.","journal-title":"Neurology"},{"key":"30200192_CR62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette\u2019s syndrome: a comparative double-blind parallel group study.J Clin Psychiatry 62: 50\u201356, 2001.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR63","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"DL Gilbert","year":"2004","unstructured":"Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.J Am Acad Child Adolesc Psychiatry 43: 206\u2013214, 2004.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"GR Gaffney","year":"2002","unstructured":"Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome.J Am Acad Child Adolesc Psychiatry 41: 330\u2013336, 2002.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder.J Clin Psychiatry 62: 290\u2013294, 2001.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindler SD, Aschauser HN, DeZwaan M, Willinger U, Resinger E et al. Effective open-label treatment of Tourette\u2019s disorder with olanzapine.Int Clin Psychopharmacol 15: 23\u201328, 2000.","journal-title":"Int Clin Psychopharmacol"},{"key":"30200192_CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G et al. Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study.J Am Acad Child Adolesc Psychiatry 39: 292\u2013299, 2000.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"NM Mukaddes","year":"2003","unstructured":"Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette\u2019s disorder.J Child Adolesc Psychopharmacol 13: 295\u2013299, 2003.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.jcp.0000150229.69124.66","volume":"25","author":"A Kastrup","year":"2005","unstructured":"Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in Tourette syndrome with aripiprazole.J Clin Psychopharmacol 25: 94\u201396, 2005.","journal-title":"J Clin Psychopharmacol"},{"key":"30200192_CR70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"CH Eggers","year":"1988","unstructured":"Eggers CH, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride.Eur Arch Psychiatry Neurol Sci 237: 223\u2013229, 1988.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"30200192_CR71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"3","author":"MM Robertson","year":"1990","unstructured":"Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride.Clin Neuropharmacol 3: 229\u2013235, 1990.","journal-title":"Clin Neuropharmacol"},{"key":"30200192_CR72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.145.5.621","volume":"145","author":"RD Bruun","year":"1988","unstructured":"Bruun RD. Subtle and unrecognized side effects of neuroleptic treatment in children with Tourette\u2019s disorder.Am J Psychiatry 145: 621\u2013624, 1988.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR73","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature.J Clin Psychiatry 62: 22\u201331, 2001.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR74","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","volume":"161","author":"A Martin","year":"2004","unstructured":"Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, Mc-Cracken J et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.Am J Psychiatry 161: 1125\u20131127, 2004.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","volume":"70","author":"JM Meyer","year":"2004","unstructured":"Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review.Schizophr Res 70: 1\u201317, 2004.","journal-title":"Schizophr Res"},{"key":"30200192_CR76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11910-001-0016-8","volume":"1","author":"HS Singer","year":"2001","unstructured":"Singer HS. The treatment of tics.Cur Neurol Neurosci Rep 1: 195\u2013202, 2001.","journal-title":"Cur Neurol Neurosci Rep"},{"key":"30200192_CR77","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0009-9236(99)70117-7","volume":"65","author":"Z Desta","year":"1999","unstructured":"Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).Clin Pharmacol Ther 65: 10\u201320, 1999.","journal-title":"Clin Pharmacol Ther"},{"key":"30200192_CR78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1024122706337","volume":"74","author":"W Zareba","year":"2003","unstructured":"Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation.Psychiatr Q 74: 291\u2013306, 2003.","journal-title":"Psychiatr Q"},{"key":"30200192_CR79","unstructured":"U.S. Food and Drug Administration. NDA 20-825 approval letter and labeling for ziprasione. Available at: http:\/\/www.fda.gov\/ cder\/foi\/label, 2001. Accessed March 2004."},{"key":"30200192_CR80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","volume":"44","author":"J Blair","year":"2005","unstructured":"Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.J Am Acad Child Adolesc Psychiatry 44: 73\u201379, 2005.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(79)91614-3","volume":"2","author":"DJ Cohen","year":"1979","unstructured":"Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette\u2019s syndrome.Lancet 2: 551\u2013553, 1979.","journal-title":"Lancet"},{"key":"30200192_CR82","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1097\/00004583-199710001-00007","volume":"36","author":"American Academy of Child and Adolescent Psychiatry","year":"1997","unstructured":"American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 36: 85S-121S, 1997.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR83","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.CIR.99.7.979","volume":"99","author":"H Gutgesell","year":"1999","unstructured":"Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation 99: 979\u2013982, 1999.","journal-title":"Circulation"},{"key":"30200192_CR84","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archpsyc.1986.01800120054011","volume":"43","author":"JF Leckman","year":"1986","unstructured":"Leckman JF, Ort S, Caruso KA, Anderson GM, Riddle MA, Cohen DJ. Rebound phenomena in Tourette\u2019s syndrome after abrupt withdrawal of clonidine.Arch Gen Psychiatry 43: 1168\u20131176, 1986.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR85","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E et al. Guanfacine in the treatment of children with tic disorders and ADHD: a placebo-controlled study.Am J Psychiatry 158: 1067\u20131074, 2001.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR86","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","volume":"25","author":"DD Cummings","year":"2002","unstructured":"Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study.Clin Neuropharmacol 25: 325\u2013332, 2002.","journal-title":"Clin Neuropharmacol"},{"key":"30200192_CR87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002826-199304000-00009","volume":"16","author":"R Kurlan","year":"1993","unstructured":"Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette\u2019s syndrome.Clin Neuropharmacol 16: 167\u2013172, 1993.","journal-title":"Clin Neuropharmacol"},{"key":"30200192_CR88","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/cap.1997.7.75","volume":"7","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette\u2019s syndrome: a double-blind placebo-controlled study.J Child Adolesc Psychopharmacol 7: 75, 1997.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR89","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","volume":"38","author":"J Jankovic","year":"1988","unstructured":"Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.Neurology 38: 391\u2013394, 1988.","journal-title":"Neurology"},{"key":"30200192_CR90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders.Neurology 48: 358\u2013362, 1997.","journal-title":"Neurology"},{"key":"30200192_CR91","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mds.870120320","volume":"12","author":"JF Lipinski","year":"1997","unstructured":"Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide.Mov Disord 12: 402\u2013407, 1997.","journal-title":"Mov Disord"},{"key":"30200192_CR92","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.54.6.1310","volume":"54","author":"DL Gilbert","year":"2000","unstructured":"Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette\u2019s syndrome improvement with pergolide in a randomized, double-blind, crossover trial.Neurology 54: 1310\u20131315. 2000.","journal-title":"Neurology"},{"key":"30200192_CR93","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/01.WNL.0000044058.64647.7E","volume":"60","author":"DL Gilbert","year":"2003","unstructured":"Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children.Neurology 60: 606\u2013611, 2003.","journal-title":"Neurology"},{"key":"30200192_CR94","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mds.870090306","volume":"9","author":"CG Goetz","year":"1994","unstructured":"Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette\u2019s syndrome: double-blind, placebo-controlled clinical trial.Mov Disord 9: 315\u2013317, 1994.","journal-title":"Mov Disord"},{"key":"30200192_CR95","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y. Tics in Tourette syndrome: new treatment options.J Child Neurol 14: 316\u2013319, 1999.","journal-title":"J Child Neurol"},{"key":"30200192_CR96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/mds.870090315","volume":"9","author":"J Jankovic","year":"1994","unstructured":"Jankovic J. Botulinum toxin in the treatment of dystonic tics.Mov Disord 9: 347\u2013349, 1994.","journal-title":"Mov Disord"},{"key":"30200192_CR97","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics.Arch Neurol 57: 1190\u20131193, 2000.","journal-title":"Arch Neurol"},{"key":"30200192_CR98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Manas","year":"2001","unstructured":"Manas C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.Neurology 56: 605\u2013610, 2001.","journal-title":"Neurology"},{"key":"30200192_CR99","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","volume":"24","author":"M Porta","year":"2004","unstructured":"Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A.Neurol Sci 24: 420\u2013423, 2004.","journal-title":"Neurol Sci"},{"key":"30200192_CR100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0317167100025129","volume":"3","author":"M Gonce","year":"1977","unstructured":"Gonce M, Barbeau A. Seven cases of Gilles de la Tourette\u2019s syndrome: partial relief with clonazepam. A pilot study.Can J Neurol Sci 3: 279\u2013283, 1977.","journal-title":"Can J Neurol Sci"},{"key":"30200192_CR101","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00004583-199403000-00014","volume":"33","author":"RJ Steingard","year":"1994","unstructured":"Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD.J Am Acad Child Adolesc Psychiatry 33: 394\u2013399, 1994.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR102","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199403000-00011","volume":"33","author":"F Graae","year":"1994","unstructured":"Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders.J Am Acad Child Adolesc Psychiatry 33: 372\u2013376, 1994.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR103","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial.Neurology 56: 599\u2013604, 2001.","journal-title":"Neurology"},{"key":"30200192_CR104","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.158.6.968-a","volume":"158","author":"FS Abuzzahab","year":"2001","unstructured":"Abuzzahab FS, Brown VL. Control of Tourette\u2019s syndrome with topiramate.Am J Psychiatry 158: 968, 2001.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/mds.20385","volume":"20","author":"Y Awaad","year":"2005","unstructured":"Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.Mov Disord 20: 714\u2013718, 2005.","journal-title":"Mov Disord"},{"key":"30200192_CR106","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ophtha.2003.12.052","volume":"111","author":"FW Fraunfelder","year":"2004","unstructured":"Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.Ophthalmology 111: 1275\u20131279, 2004.","journal-title":"Ophthalmology"},{"key":"30200192_CR107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","volume":"43","author":"PR Sanberg","year":"1989","unstructured":"Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome.Biomed Pharmacother 43: 19, 1989.","journal-title":"Biomed Pharmacother"},{"key":"30200192_CR108","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/0006-3223(92)90315-Q","volume":"15","author":"BJ McConville","year":"1992","unstructured":"McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette\u2019s disorder.Biol Psychiatry 15: 832\u2013840, 1992.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR109","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v62n0908","volume":"62","author":"AA Silver","year":"2001","unstructured":"Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette\u2019s disorder: a double-blind placebo-controlled study.J Clin Psychiatry 62: 707\u2013714, 2001.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/da.10035","volume":"16","author":"RD Shytle","year":"2002","unstructured":"Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.Depress Anxiety 16: 89\u201392, 2002.","journal-title":"Depress Anxiety"},{"key":"30200192_CR111","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","volume":"40","author":"AA Silver","year":"2001","unstructured":"Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette\u2019s disorder.J Am Acad Child Adolesc Psychiatry 40: 1103\u20131110, 2001.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR112","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00004714-199808000-00013","volume":"18","author":"BS Peterson","year":"1998","unstructured":"Peterson BS, Zhang H, Bondi C, Naftolin F, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette\u2019s syndrome.J Clin Psychopharmacol 18: 324\u2013331, 1998.","journal-title":"J Clin Psychopharmacol"},{"key":"30200192_CR113","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/archpsyc.1989.01810120030006","volume":"46","author":"HL Leonard","year":"1989","unstructured":"Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL et al. Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents.Arch Gen Psychiatry 46: 1088\u20131092, 1989.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR114","first-page":"54","volume":"26","author":"J DeVeaugh-Geiss","year":"1990","unstructured":"DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.Psychopharmacol Bull 26: 54\u201359, 1990.","journal-title":"Psychopharmacol Bull"},{"key":"30200192_CR115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004583-199201000-00008","volume":"31","author":"J DeVeaugh-Geiss","year":"1992","unstructured":"DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial.J Am Acad Child Adolesc Psychiatry 31: 45\u201349, 1992.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR116","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1176\/appi.ps.54.8.1111","volume":"54","author":"A Kaplan","year":"2003","unstructured":"Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder.Psychiatr Serv 54: 1111\u20131118. 2003.","journal-title":"Psychiatr Serv"},{"key":"30200192_CR117","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp031002","volume":"350","author":"MA Jenike","year":"2004","unstructured":"Jenike MA. Clinical practice. Obsessive-compulsive disorder.N Engl J Med 350: 259\u2013265, 2004.","journal-title":"N Engl J Med"},{"key":"30200192_CR118","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","volume":"16","author":"SA Montgomery","year":"2001","unstructured":"Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.Int Clin Psychopharmacol 16: 75\u201386, 2001.","journal-title":"Int Clin Psychopharmacol"},{"key":"30200192_CR119","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","volume":"280","author":"JS March","year":"1998","unstructured":"March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.JAMA 280: 1752\u20131156, 1998.","journal-title":"JAMA"},{"key":"30200192_CR120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","volume":"40","author":"DA Geller","year":"2001","unstructured":"Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S et al. Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.J Am Acad Child Adolesc Psychiatry 40: 773\u2013779, 2001.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","volume":"40","author":"MA Riddle","year":"2001","unstructured":"Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghom JL, Gaffney G et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.J Am Acad Child Adolesc Psychiatry 40: 222\u2013229, 2001.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR122","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00004583-200212000-00014","volume":"41","author":"MR Liebowitz","year":"2002","unstructured":"Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.J Am Acad Child Adolesc Psychiatry 41: 1431\u20131438, 2002.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR123","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","volume":"43","author":"DA Geller","year":"2004","unstructured":"Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multi-center, double-blind, placebo-controlled trial.J Am Acad Child Adolesc Psychiatry 43: 1387\u20131396, 2004.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR124","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","volume":"292","author":"Pediatric OCD Treatment Study (POTS) Team","year":"2004","unstructured":"Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial.JAMA 292: 1969\u20131976, 2004.","journal-title":"JAMA"},{"key":"30200192_CR125","first-page":"193","volume":"3","author":"MA Riddle","year":"1991","unstructured":"Riddle MA, King RA, Hardin MT, Scahill L, Ort SI, Leckman JF. Behavioral side effects of fluoxetine.J Child Adolesc Psychopharmacol 3: 193\u2013198, 1991.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR126","unstructured":"U.S. Food and Drug Administration. Labeling Change Request Letter for Antidepressant Medications. Available at: http:\/\/www. fda.gov\/cder\/drug\/antidpressants\/SSRI labeling, Accessed October 15, 2004."},{"key":"30200192_CR127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00004583-199103000-00003","volume":"30","author":"RA King","year":"1991","unstructured":"King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment.J Am Acad Child Adolesc Psychiatry 30: 179\u2013186, 1991.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/cap.1996.6.211","volume":"6","author":"JR Oesterheld","year":"1996","unstructured":"Oesterheld JR. Erythromycin and clomipramine: noncompetitive inhibition of demethylation.J Child Adolesc Psychopharmacol 6: 211\u2013213, 1996.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/ajp.150.8.1164","volume":"150","author":"JF Rosenbaum","year":"1993","unstructured":"Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression. Part 2: Neuroendocrine correlates and changes following fluoxetine treatment.Am J Psychiatry 150: 1164\u20131168, 1993.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR130","first-page":"20","volume":"63","author":"E Hollander","year":"2002","unstructured":"Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment.J Clin Psychiatry 63: 20\u201329, 2002.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR131","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/00128072-200103080-00006","volume":"3","author":"CK Varley","year":"2001","unstructured":"Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications.Paediatr Drugs 3: 613\u2013627, 2001.","journal-title":"Paediatr Drugs"},{"key":"30200192_CR132","first-page":"2","volume":"58","author":"Expert Consensus Panel for Obsessive-Compulsive Disorder","year":"1997","unstructured":"Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder.J Clin Psychiatry 58: 2\u201372, 1997.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR133","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/070674378402900211","volume":"29","author":"LB Wameke","year":"1984","unstructured":"Wameke LB. The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder.Can J Psychiatry 29: 135\u2013141, 1984.","journal-title":"Can J Psychiatry"},{"key":"30200192_CR134","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-977X(97)00048-5","volume":"8","author":"LM Koran","year":"1998","unstructured":"Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.Eur Neuropsychopharmacol 8: 121\u2013126, 1998.","journal-title":"Eur Neuropsychopharmacol"},{"key":"30200192_CR135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0006-3223(97)00373-9","volume":"44","author":"FR Sallee","year":"1998","unstructured":"Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks.Biol Psychiatry 44: 220\u2013227, 1998.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR136","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/00004583-199610000-00017","volume":"35","author":"LL Greenhill","year":"1996","unstructured":"Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers.J Am Acad Child Adolesc Psychiatry 35: 1304\u20131313, 1996.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR137","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-1781(91)90126-A","volume":"36","author":"J Elia","year":"1991","unstructured":"Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders?Psychiatr Res 36: 141\u2013155, 1991.","journal-title":"Psychiatr Res"},{"key":"30200192_CR138","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.35.9.1346","volume":"35","author":"G Erenberg","year":"1985","unstructured":"Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette\u2019s syndrome: effects of stimulant drugs.Neurology 35: 1346\u20131348. 1985.","journal-title":"Neurology"},{"key":"30200192_CR139","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1469-8749.1974.tb02715.x","volume":"16","author":"GS Golden","year":"1974","unstructured":"Golden GS. Gilles de la Tourette\u2019s syndrome following methyl-phenidate administration.Dev Med Child Neurol 16: 76\u201378, 1974.","journal-title":"Dev Med Child Neurol"},{"key":"30200192_CR140","first-page":"1729","volume":"26","author":"TL Lowe","year":"1992","unstructured":"Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette\u2019s syndrome.JAMA 26: 1729\u20131731, 1992.","journal-title":"JAMA"},{"key":"30200192_CR141","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/archpedi.1994.02170080089017","volume":"148","author":"PH Lipkin","year":"1994","unstructured":"Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.Arch Pediatr Adolesc Med 148: 859\u2013861, 1994.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"30200192_CR142","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/cap.1995.5.205","volume":"5","author":"MA Riddle","year":"1995","unstructured":"Riddle MA, Lynch KA, Scahill L. Methylphenidate discontinuation during long-term treatment of children with Tourette\u2019s disorder and attention deficit hyperactivity disorder: a pilot study.J Child Adolesc Psychopharmacol 5: 205\u2013214, 1995.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR143","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/comp.2001.23145","volume":"42","author":"CK Varley","year":"2001","unstructured":"Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.Comp Psychiatry 42: 228\u2013233, 2001.","journal-title":"Comp Psychiatry"},{"key":"30200192_CR144","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1542\/peds.86.2.184","volume":"86","author":"RA Barkley","year":"1992","unstructured":"Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.Pediatrics 86: 184\u2013192, 1992.","journal-title":"Pediatrics"},{"key":"30200192_CR145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0165-1781(90)90151-T","volume":"33","author":"BG Borcherding","year":"1990","unstructured":"Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor\/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?Psychiatry Res 33: 83\u201394, 1990.","journal-title":"Psychiatry Res"},{"key":"30200192_CR146","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00004583-199705000-00008","volume":"36","author":"FX Castellanos","year":"1997","unstructured":"Castellanos FX, Geidd JN, Elia J. Controlled stimulant treatment of ADHD and comorbid Tourette\u2019s syndrome: effects of stimulant and dose.J Am Acad Child Adolesc Psychiatry 36: 589\u2013596, 1997.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR147","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/archpsyc.1995.03950180030005","volume":"52","author":"KD Gadow","year":"1995","unstructured":"Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder.Arch Gen Psychiatry 52: 444\u2013455. 1995.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR148","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"Tourette Syndrome Study Group","year":"2002","unstructured":"Tourette Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial.Neurology 58: 527\u2013536, 2002.","journal-title":"Neurology"},{"key":"30200192_CR149","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archpsyc.56.4.330","volume":"56","author":"KD Gadow","year":"1999","unstructured":"Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity dsorder and chronic multiple tic disorder.Arch Gen Psychiatry 56: 330\u2013336, 1999.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR150","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/00004583-199908000-00009","volume":"38","author":"SF Law","year":"1999","unstructured":"Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?J Am Acad Child Adolesc Psychiatry 38: 944\u2013951. 1999.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR151","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00004583-198909000-00022","volume":"28","author":"J Biederman","year":"1989","unstructured":"Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy.J Am Acad Child Adolesc Psychiatry 28: 777\u2013784, 1989.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR152","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.95.1.74","volume":"95","author":"H Singer","year":"1995","unstructured":"Singer H, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: a double-blind placebo-controlled study with clonidine and desipramine.Pediatrics 95: 74\u201381, 1995.","journal-title":"Pediatrics"},{"key":"30200192_CR153","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","volume":"59","author":"T Spencer","year":"2002","unstructured":"Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder.Arch Gen Psychiatry 59: 649\u2013656, 2002.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR154","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00004583-199307000-00013","volume":"32","author":"MA Riddle","year":"1993","unstructured":"Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine.J Am Acad Child Adolesc Psychiatry 32: 792\u2013797, 1993.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00004583-199505000-00017","volume":"34","author":"L Barrickman","year":"1995","unstructured":"Barrickman L, Perry P, Allen A, Kuperman S, Arndt S, Herrmann K, et al. Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 34: 649\u2013657, 1995.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR156","first-page":"120","volume":"23","author":"CD Casat","year":"1987","unstructured":"Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder.Psychopharmacol Bull 23: 120\u2013122, 1987.","journal-title":"Psychopharmacol Bull"},{"key":"30200192_CR157","first-page":"198","volume":"25","author":"CD Casat","year":"1989","unstructured":"Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder.Psychopharmacol Bull 25: 198\u2013201, 1989.","journal-title":"Psychopharmacol Bull"},{"key":"30200192_CR158","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/00004583-199610000-00018","volume":"34","author":"CK Conners","year":"1996","unstructured":"Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity.J Am Acad Child Adolesc Psychiatry 34: 1314\u20131321, 1996.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR159","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004583-199301000-00030","volume":"32","author":"T Spencer","year":"1993","unstructured":"Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette\u2019s syndrome.J Am Acad Child Adolesc Psychiatry 32: 211\u2013214, 1993.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0736-4679(02)00522-X","volume":"23","author":"MG Belson","year":"2002","unstructured":"Belson MG, Kelley TR. Bupropion exposures: clinical manifestations and medical outcome.J Emerg Med 23: 223\u2013230, 2002.","journal-title":"J Emerg Med"},{"key":"30200192_CR161","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1469-7610.1996.tb01445.x","volume":"37","author":"JK Buitelaar","year":"1996","unstructured":"Buitelaar JK, van der Gaag RJ, Swaab-Bameveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder: clinical efficacy and side-effects.J Child Psychol Psychiatry 37: 587\u2013595, 1996.","journal-title":"J Child Psychol Psychiatry"},{"key":"30200192_CR162","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.46.4.965","volume":"46","author":"A Feigin","year":"1996","unstructured":"Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsapulos T, Brower CA et al. A controlled trial of deprenyl in children with Tourette\u2019s syndrome and attention deficit hyperactivity disorder.Neurology 46: 965\u2013968, 1996.","journal-title":"Neurology"},{"key":"30200192_CR163","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-7138(09)60065-0","volume":"24","author":"RD Hunt","year":"1985","unstructured":"Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.J Am Acad Child Adolesc Psychiatry 24: 617\u2013629, 1985.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR164","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/000992280003900102","volume":"39","author":"DF Connor","year":"2000","unstructured":"Connor DF, Barkery RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.Clin Pediatr 39: 15\u201325, 2000.","journal-title":"Clin Pediatr"},{"key":"30200192_CR165","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/00004583-199407000-00015","volume":"33","author":"MD Rapport","year":"1994","unstructured":"Rapport MD, Denney C, DuPaul GJ, Gardener M. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children.J Am Acad Child Adolesc Psychiatry 33: 882\u2013893, 1994.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR166","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004583-199501000-00013","volume":"34","author":"RD Hunt","year":"1995","unstructured":"Hunt RD, Amsten AFT, Asbell MD. An open trial of guanfacine in phe nidatef or attention deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 34: 50\u201354, 1995.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR167","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.1995.5.215","volume":"5","author":"JP Horrigan","year":"1995","unstructured":"Horrigan JP, Bamhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys.J Child Adolesc Psychopharmacol 5: 215\u2013223, 1995.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"30200192_CR168","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","volume":"34","author":"PB Chappell","year":"1995","unstructured":"Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Amsten A et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: preliminary clinical experience.J Am Acad Child Adolesc Psychiatry 34: 1140\u20131146, 1995.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR169","volume-title":"Stimulant drugs and ADHD: basic and clinical neuroscience","author":"MV Solanto","year":"2001","unstructured":"Solanto MV, Amsten AFT, Catellanos FX. Stimulant drugs and ADHD: basic and clinical neuroscience. New York: Oxford, 2001."},{"key":"30200192_CR170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00004583-200301000-00016","volume":"42","author":"D Sukhodolsky","year":"2003","unstructured":"Sukhodolsky D, Scahill L, Zhang H, Peterson BS, King RA, Lombroso PJ et al. Disruptive behavior in children with Tourette\u2019 s syndrome: association of ADHD comorbidity, tic severity, and functional impairment.J Am Acad Child Adolesc Psychiatry 42: 98\u2013105, 2003.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR171","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1542\/peds.108.5.e83","volume":"108","author":"D Michelson","year":"2001","unstructured":"Michelson D, Faries D, Wemicke J, Kelsey D, Kendrick K, Sallee FR et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.Pediatrics 108: E83, 2001.","journal-title":"Pediatrics"},{"key":"30200192_CR172","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","volume":"159","author":"D Michelson","year":"2002","unstructured":"Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.Am J Psychiatry 159: 1896, 2002.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR173","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0006-3223(97)00025-5","volume":"43","author":"ML Berthier","year":"1998","unstructured":"Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients with Tourette\u2019s syndrome: a clinical study.Biol Psychiatry 43: 364\u2013370, 1998.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR174","first-page":"804","volume":"41","author":"BG Comings","year":"1987","unstructured":"Comings BG, Comings DE. A controlled study of Tourette syndrome. V. Depression and mania.Am J Hum Genet 41: 804\u2013821, 1987.","journal-title":"Am J Hum Genet"},{"key":"30200192_CR175","first-page":"761","volume":"41","author":"DE Comings","year":"1987","unstructured":"Comings DE, Comings BG. A controlled study of Tourette syndrome. III. Phobias and panic attacks.Am J Hum Genet 41: 761\u2013781, 1987.","journal-title":"Am J Hum Genet"},{"key":"30200192_CR176","first-page":"288","volume":"51","author":"DE Comings","year":"1990","unstructured":"Comings DE, Comings BG. A controlled family history study of Tourette\u2019s syndrome. III. Affective and other disorders.J Clin Psychiatry 51: 288\u2013291, 1990.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR177","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00004583-200005000-00009","volume":"39","author":"BJ Coffey","year":"2000","unstructured":"Coffey BJ, Biederman J, Smoller JW, Geller DA, Sarin P, Schwartz S et al. Anxiety disorders and tic severity in juveniles with Tourette\u2019s disorder.J Am Acad Child Adolesc Psychiatry 39: 562\u2013568, 2000.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR178","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0733-8619(05)70312-1","volume":"15","author":"BJ Coffey","year":"1997","unstructured":"Coffey BJ, Park KS. Behavioral and emotional aspects of Tourette syndrome.Neurol Clin 15: 277\u2013289, 1997.","journal-title":"Neurol Clin"},{"key":"30200192_CR179","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1176\/ajp.152.11.1646","volume":"152","author":"J Kerbeshian","year":"1995","unstructured":"Kerbeshian J, Burd L, Klug MG. Comorbid Tourette\u2019s disorder and bipolar disorder: an etiologic perspective.Am J Psychiatry 152: 1646\u20131651, 1995.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajmg.1320600206","volume":"60","author":"DE Comings","year":"1995","unstructured":"Comings DE. Role of genetic factors in depression based on studies of Tourette syndrome and ADHD probands and their relatives.Am J Med Genet 60: 111\u2013121, 1995.","journal-title":"Am J Med Genet"},{"key":"30200192_CR181","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/archneur.1997.00550160101023","volume":"54","author":"D Palumbo","year":"1997","unstructured":"Palumbo D, Maughan A, Kurlan R. Hypothesis: III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome.Arch Neurol 54: 475\u2013483, 1997.","journal-title":"Arch Neurol"},{"key":"30200192_CR182","first-page":"79","volume":"85","author":"RA King","year":"2001","unstructured":"King RA, Scahill L. Emotional and behavioral difficulties associated with Tourette syndrome.Adv Neurol 85: 79\u201388, 2001.","journal-title":"Adv Neurol"},{"key":"30200192_CR183","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0193-953X(02)00107-7","volume":"26","author":"M Fava","year":"2003","unstructured":"Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.Psychiatr Clin North Am 26: 457\u2013494, 2003.","journal-title":"Psychiatr Clin North Am"},{"key":"30200192_CR184","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0006-3223(01)01149-0","volume":"49","author":"GJ Emslie","year":"2001","unstructured":"Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment.Biol Psychiatry 49: 1082\u20131090, 2001.","journal-title":"Biol Psychiatry"},{"key":"30200192_CR185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4088\/JCP.v64n0108","volume":"64","author":"GS Sachs","year":"2003","unstructured":"Sachs GS. Decision tree for the treatment of bipolar disorder.J Clin Psychiatry 64: 35\u201340, 2003.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR186","first-page":"3","volume":"57","author":"Expert Consensus Guideline Series","year":"1996","unstructured":"Expert Consensus Guideline Series. Treatment of bipolar disorder.J Clin Psychiatry 57: 3\u201388, 1996.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR187","first-page":"24","volume":"64","author":"JM Gorman","year":"2003","unstructured":"Gorman JM. Treating generalized anxiety disorder.J Clin Psychiatry 64: 24\u201329, 2003.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR188","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/00004583-200010000-00014","volume":"39","author":"CL Budman","year":"2000","unstructured":"Budman CL, Bruun RD, Park KS, Lesser M, Olson M. Explosive outbursts in children with Tourette\u2019s disorder.J Am Acad Child Adoles Psychiatry 39: 1270\u20131276, 2000.","journal-title":"J Am Acad Child Adoles Psychiatry"},{"key":"30200192_CR189","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S0012162200000839","volume":"42","author":"RD Freeman","year":"2000","unstructured":"Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries.Dev Med Child Neurol 42: 436\u2013447, 2000.","journal-title":"Dev Med Child Neurol"},{"key":"30200192_CR190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4088\/JCP.v59n1104","volume":"59","author":"RD Bruun","year":"1998","unstructured":"Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette\u2019s disorder.J Clin Psychiatry 59: 581\u2013584, 1998.","journal-title":"J Clin Psychiatry"},{"key":"30200192_CR191","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2002","unstructured":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism for serious behavioral problems.N Engl J Med 347: 314\u2013321, 2002.","journal-title":"N Engl J Med"},{"key":"30200192_CR192","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.Am J Psychiatry 159: 1337\u20131346, 2002.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR193","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.157.5.818","volume":"157","author":"SJ Donovan","year":"2000","unstructured":"Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.Am J Psychiatry 157: 818\u2013820, 2000.","journal-title":"Am J Psychiatry"},{"key":"30200192_CR194","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00004583-199509000-00011","volume":"34","author":"PJ Lombroso","year":"1995","unstructured":"Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.J Am Acad Child Adolesc Psychiatry 34: 1147\u20131152, 1995.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"30200192_CR195","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"CJ McDougle","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics.Arch Gen Psychiatry 51: 302\u2013308, 1994.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR196","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.Arch Gen Psychiatry 57: 794\u2013801, 2000.","journal-title":"Arch Gen Psychiatry"},{"key":"30200192_CR197","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/cap.1998.8.61","volume":"8","author":"Y Figueroa","year":"1998","unstructured":"Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.J Child Adolesc Psychopharmacol 8: 61\u201367, 1998.","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["NeuroRX"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurx.2006.01.009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T21:17:04Z","timestamp":1683407824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1016\/j.nurx.2006.01.009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":197,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["30200192"],"URL":"https:\/\/doi.org\/10.1016\/j.nurx.2006.01.009","relation":{},"ISSN":["1545-5343"],"issn-type":[{"value":"1545-5343","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}